Thromboelastography with Platelet Mapping to Optimize Surgical Timing in Coronary Artery Bypass Grafting Patients on P2Y12 Receptor Blockers Therapy

被引:0
|
作者
Dambruoso, Pierpaolo
Raimondo, Pasquale [1 ,2 ,3 ]
Massaro, Fabrizia [2 ]
D'Aniello, Margherita [1 ]
Di Pinto, Giuseppe [1 ]
机构
[1] St Maria Hosp GVM Care & Res, Bari, Apulia, Italy
[2] Azienda Osped Univ Consorziale Policlin Bari, Anesthesia & Intens Care Unit II, Piazza Giulio Cesare 1 Bari, I-70121 Bari, Apulia, Italy
[3] Osped Gen Regionale F Miulli, Anesthesia & Intens Care Unit, Acquaviva Delle Fonti, Apulia, Italy
关键词
Coronary Artery Bypass; Thrombolastography; Clopidogrel; Prasugrel; Hydrochloride; Ticagrelor; Waiting Lists; THORACIC SURGEONS; CLOPIDOGREL; ASSOCIATION; GUIDELINES; SOCIETY; UPDATE; RESPONSIVENESS; MANAGEMENT; RESISTANCE;
D O I
10.21470/1678-9741-2023-0292
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: An increasing number of patients attending coronary artery bypass grafting (CABG) receive preoperative antiplatelet drugs (acetylsalicylic acid, clopidogrel, prasugrel, ticagrelor). The optimal assessment of preoperative platelet function is the aim of this study for a shorter surgical timing in patients undergoing elective coronary artery bypass grafting. Methods: This study was performed on patients presenting for first-time isolated CABG on therapy with an P2Y,2 receptor blockers loading dose (clopidogrel [300 mg] or prasugrel [60 mg] or ticagrelor [180 mg]) or P2Y,2 receptor blockers maintenance therapy at least for five days (clopidogrel [75 mg once daily], prasugrel [10 mg once daily], ticagrelor [90 mg twice daily]). All patients received simultaneously acetylsalicylate acid (100 mg daily). Exclusion criterion was emergency CABG regardless of preoperative antiplatelet and anticoagulant therapy. All patients ' data were recorded in an Excel (R) file and analyzed using RStudio (R) software. Results: Forty-eight consecutive adult patients presenting for CABG were enrolled. Preoperative thromboelastography-platelet mapping showed platelet resistance to P2Y,2 blockers receptor - 25% for clopidogrel (6/24), 33% for ticagrelor (6/18), 33% for prasugrel (2/6), and this data was useful to obtain a shorter CABG waiting time in comparison with current guidelines (2.7 vs. five days for clopidogrel, 2.5 vs. five days for ticagrelor, 3.3 vs. seven days for prasugrel). Conclusion: Preoperative thromboelastography-platelet mapping is helpful to detect harmful P2Y,2 receptor blockers resistance and to minimize CABG waiting time avoiding unnecessary and life-threatening delays.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Novel Platelet ADP P2Y12 Inhibitors in the Treatment of Acute Coronary Syndrome
    Tan, Guang-Ming
    Lam, Yat-Yin
    Yan, Bryan P.
    CARDIOVASCULAR THERAPEUTICS, 2012, 30 (04) : e167 - e173
  • [32] Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease
    Angiolillo, DJ
    Fernandez-Ortiz, A
    Bernardo, E
    Ramírez, C
    Cavallari, U
    Trabetti, E
    Sabaté, M
    Jimenez-Quevedo, P
    Hernández, R
    Moreno, R
    Escaned, J
    Alfonso, F
    Bañuelos, C
    Costa, MA
    Bass, TA
    Pignatti, PF
    Macaya, C
    THROMBOSIS RESEARCH, 2005, 116 (06) : 491 - 497
  • [33] Protease-activated receptor-mediated platelet aggregation in acute coronary syndrome patients on potent P2Y12 inhibitors
    Wadowski, Patricia P.
    Pultar, Joseph
    Weikert, Constantin
    Eichelberger, Beate
    Panzer, Benjamin
    Huber, Kurt
    Lang, Irene M.
    Koppensteiner, Renate
    Panzer, Simon
    Gremmel, Thomas
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2019, 3 (03) : 383 - 390
  • [34] Effect of preoperative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery
    Ranucci, M.
    Colella, D.
    Baryshnikova, E.
    Di Dedda, U.
    BRITISH JOURNAL OF ANAESTHESIA, 2014, 113 (06) : 970 - 976
  • [35] Clash of Oral P2Y12 Receptor Inhibitors in Acute Coronary Syndromes
    Chatzizisis, Yiannis S.
    Stefanadis, Christodoulos
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (04) : 382 - 385
  • [36] P2Y12 receptor inhibitor resistance and coronary artery disease: a bench to bedside primer for cardiovascular specialists
    So, Derek Y. F.
    Bagai, Akshay
    Tran, Uyen
    Verma, Subodh
    Mehta, Shamir R.
    CURRENT OPINION IN CARDIOLOGY, 2017, 32 (05) : 617 - 626
  • [37] Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions - Limited inhibition of the P2Y12 receptor
    Lepantalo, Aino
    Virtanen, Kari S.
    Resendiz, Julio C.
    Mikkelsson, Jussi
    Viiri, Leena E.
    Karhunen, Pekka J.
    Lassila, Riita
    THROMBOSIS RESEARCH, 2009, 124 (02) : 193 - 198
  • [38] Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study
    Deharo, Pierre
    Quilici, Jacques
    Bonnet, Guillaume
    Grosdidier, Charlotte
    Morange, Pierre
    Alessi, Marie-Christine
    Bonnet, Jean-Louis
    Cuisset, Thomas
    PLATELETS, 2016, 27 (08) : 791 - 795
  • [39] Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists
    Becker, Richard C.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2009, 28 (04) : 513 - 514
  • [40] P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coronary artery disease after coronary stenting
    Zoheir, Naguib
    Abd Elhamid, Samah
    Abulata, Nelly
    El Sobky, Mehry
    Khafagy, Doaa
    Mostafa, Amr
    BLOOD COAGULATION & FIBRINOLYSIS, 2013, 24 (05) : 525 - 531